These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23128835)

  • 21. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention.
    Zhang RY; Zhu ZB; Zhang Q; Yang ZK; Hu J; Lv AK; Zhang JS; Shen WF
    Int J Cardiol; 2009 Jul; 136(1):72-9. PubMed ID: 18653250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosage of enoxaparin among obese and renal impairment patients.
    Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
    Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of sparfloxacin in patients with renal impairment.
    Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH
    Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal insufficiency increases mortality in acute coronary syndromes regardless of TIMI risk score.
    Dudek D; Chyrchel B; Siudak Z; Depukat R; Chyrchel M; Dziewierz A; Mielecki W; Rakowski T; Rzeszutko Ł; Dubiel J
    Kardiol Pol; 2008 Jan; 66(1):28-34; discussion 35-6. PubMed ID: 18266185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.
    Mismetti P; Samama CM; Rosencher N; Vielpeau C; Nguyen P; Deygas B; Presles E; Laporte S;
    Thromb Haemost; 2012 Jun; 107(6):1151-60. PubMed ID: 22476471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
    Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
    J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes.
    LaPointe NM; Chen AY; Alexander KP; Roe MT; Pollack CV; Lytle BL; Ohman ME; Gibler BW; Peterson ED
    Arch Intern Med; 2007 Jul; 167(14):1539-44. PubMed ID: 17646609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment.
    Karaoui LR; Tawil S; Salameh P; Chamoun N
    J Int Med Res; 2019 Jan; 47(1):225-234. PubMed ID: 30259770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.
    Healy MF; Speroni KG; Eugenio KR; Murphy PM
    Ann Pharmacother; 2012 Apr; 46(4):477-83. PubMed ID: 22474135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus-eluting stent: 1- and 2-year data from the E-Five Registry.
    Rothman MT; Jain AK;
    Catheter Cardiovasc Interv; 2012 Nov; 80(6):885-92. PubMed ID: 22517785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM; Jackevicius CA; Yeo E
    Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal profiles of anticoagulants.
    Harder S
    J Clin Pharmacol; 2012 Jul; 52(7):964-75. PubMed ID: 21610202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: a retrospective study.
    Maru S; Abe T; Shinohara N; Sazawa A; Maruyama S; Harabayashi T; Suzuki S; Nonomura K
    Int J Urol; 2012 Feb; 19(2):110-6. PubMed ID: 22126100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
    Berger PB; Best PJ; Topol EJ; White J; DiBattiste PM; Chan AW; Kristensen SD; Herrmann HC; Moliterno DJ
    Am Heart J; 2005 May; 149(5):869-75. PubMed ID: 15894970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
    Hacobian M; Shetty R; Niles CM; Gerhard-Herman M; Vallurupalli N; Baroletti S; McKean SC; Sonis J; Parasuraman S; Kosowsky JM; Goldhaber SZ
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):21-5. PubMed ID: 19147527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
    Hammerstingl C; Omran H
    Europace; 2011 Sep; 13(9):1304-10. PubMed ID: 21508005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine.
    Rashid ST; Salman M; Agarwal S; Hamilton G
    Eur J Vasc Endovasc Surg; 2006 Sep; 32(3):294-9. PubMed ID: 16716614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.